Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Roche (RHHBY) has hired a senior executive from Novo Nordisk (NVO) as it prepares to enter the competitive market for obesity drugs, ...

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Stocks sold off globally on Monday, as fears of an economic downturn in the US, the world's largest economy, gripped markets. The main US index, the S&P 500 (^GSPC), fell 2.7%, while the tech-focused ...